Figure 1.

Median serum creatinine (μmol/L) recovery in patients presenting with Gram-negative bacteraemia and concurrent AKI stage ≥2; for all patients studied (n = 112) and also by aminoglycoside dosing received [FD AG, full dose aminoglycoside (5 and 15 mg/kg of gentamicin and amikacin, respectively), n = 54; LD AG, low dose aminoglycoside (2.5 and 7.5 mg/kg of gentamicin and amikacin, respectively), n = 33; or nil AG, no aminoglycoside treatment received, n = 20, as defined by the CWFT Adult Aminoglycoside Dosing guide (2021)].